Generic Supply Chain | Association for Accessible Medicines

AAM Calls for Increased Voluntary Licensing of Covid Vaccines to Increase Patient Access

WASHINGTON, D.C. (August 16, 2021) — AAM and its member companies have worked extremely hard to enhance patient access to affordable treatments throughout the COVID-19 pandemic. This includes manufacturing dexamethasone, which is estimated to have saved more than 1 million lives worldwide, and producing under voluntary licensing agreements leading vaccines and other therapeutics for use by patients in developing countries.

Read more about AAM Calls for Increased Voluntary Licensing of Covid Vaccines to Increase Patient Access

A Roadmap for Access

We must secure sustainable markets to ensure patient access to generic and biosimilar medicines

This article first appeared in The Medicine Maker on March 22, 2021.

Read more about A Roadmap for Access

The Generics and Biosimilars Industry Has a Plan to Secure Our Medicines — #SecureOurMeds

Submitted by eklinger on Thu, 03/04/2021 - 09:49

The U.S. generics and biosimilars industry, makers of 90% of our nation's prescription medicines, has a plan to "#SecureOurMeds." We already produce billions of doses of medicine right here in America, and our plan ensures continued patient access through COVID and beyond.

Learn more about our path forward at: https://www.secureourmeds.org/

Read more about The Generics and Biosimilars Industry Has a Plan to Secure Our Medicines — #SecureOurMeds

Roadmaps for Ensuring Patient Access to Generic and Biosimilar Medicines: Securing Sustainable Markets

This paper examines the challenges to market sustainability for generic and biosimilar medicines that have cleared the regulatory and patent hurdles to obtain FDA approval and launch into the U.S. market. It is the first in a series of AAM papers that will highlight challenges to the overall sustainability of the generics and biosimilars industry.

Read more about Roadmaps for Ensuring Patient Access to Generic and Biosimilar Medicines: Securing Sustainable Markets

AAM Outlines Policy Solutions for Sustained Patient Access to Generic and Biosimilar Medicines

Association for Accessible Medicines Unveils Policy Agenda for
Biden Administration and 117th Congress
Outlines Policy Solutions to Support Long-Term Sustainability of Generic and Biosimilar Medicines

New Campaign Highlights Lifesaving Role Generic Drugs Have Played in Treatment of COVID-19
Report Series Examines Threats to Patient Access and Affordability

Read more about AAM Outlines Policy Solutions for Sustained Patient Access to Generic and Biosimilar Medicines

While We Await the Vaccine, We Can Trust in Generic Drugs

This article first appeared in Managed Healthcare Executive on February 1, 2021.

Read more about While We Await the Vaccine, We Can Trust in Generic Drugs

AAM’s Recommendations to #SecureOurMeds

Generic and biosimilar medicines are a proven solution to lowering drug costs, and the use of these medicines saved more than $313 billion in 2019 alone. At a time of high economic insecurity, access to more-affordable generic and biosimilars means patients are more likely to fill and use a generic drug prescription.

Read more about AAM’s Recommendations to #SecureOurMeds

AAM Statement on Biden’s Executive Orders to Strengthen America’s COVID Response

WASHINGTON, DC (January 21, 2020) — The Association for Accessible Medicines (AAM) strongly endorses the Biden administration’s executive orders to strengthen America’s response to the COVID pandemic. Generic medicines have been instrumental in treating COVID patients with severe conditions, serving as a bridge until the COVID vaccines are widely available. AAM’s members are ready to partner with the Biden administration to ensure reliable and predictable access to these vital therapies.

Read more about AAM Statement on Biden’s Executive Orders to Strengthen America’s COVID Response

2021 Generics and Biosimilars Outlook

This article first appeared in Chain Drug Review on January 5, 2021 as Pharmacy Outlook: Dan Leonard.

Read more about 2021 Generics and Biosimilars Outlook

Member Spotlight: Sandoz

Sandoz, the largest medicines provider in Europe and a major player globally, has a U.S. headquarters in Princeton, NJ. The Novartis division’s robust response to the COVID-19 pandemic has taken many forms:

Affordability. In early June, CEO Richard Saynor penned a LinkedIn post pledging:

Read more about Member Spotlight: Sandoz